Claims
- 1. A method of enhancing the immune response in a mammal receiving a vaccine, which comprises administering an effective immune enhancing amount of endothelial cell derived hematopoietic growth factor (EDHF) in conjunction with the administration of the vaccine.
- 2. The method of claim 1 wherein the EDHF is administered to the mammal up to 1 to 14 days before administration of the vaccine.
- 3. The method of claim 1 wherein the EDHF is co-administered with the vaccine.
- 4. The method of claim 1 wherein an adjuvant is co-administered with the vaccine.
- 5. The method of claim 4 wherein the adjuvant is a immunostimulatory molecule such as LPS, CD40L and/or CpG DNA.
- 6. The method of claim 1 wherein the mammal is a human.
- 7. A method of stimulating hematopoiesis in a mammal, which comprises administering to a mammal an hematopoietic stimulating amount of endothelial cell derived hematopoietic growth factor (EDHF).
- 8. The method of claim 7 wherein the mammal is a human.
- 9. The method of claim 8 wherein the EDHF is administered in an amount of from about 0.01 μg to about 1,000 μg per kg bodyweight.
- 10. The method of claim 7 wherein the EDHF is co-administered with one or more additional hematopoietic growth factors.
- 11. The method of claim 10 wherein the additional hematopoietic growth factors are selected from the group consisting of IL-3, GM-CSF, SCF, EPO, G-CSF, IL-1, IL-6, IL-3, IL-4, TNF-α and FLT3 ligand.
- 12. The method of claim 11 wherein the EDHF is co-administered with TNF-α and FLT3 ligand.
- 13. A method of expanding mammalian pre-dendritic myelomonocytic progenitor cells in vitro which comprises culturing mammalian pre-dendritic myelomonocyctic progenitor cells in the presence of a pre-dendritic myelomonocytic progenitor cell expanding amount of endothelial cell derived hematopoietic growth factor (EDHF).
- 14. The method of claim 13 wherein the pre-dendritic myelomonocytic progenitor cells are human CD34+ CD38+ cells.
- 15. The method of claim 13 wherein the pre-dendritic myelomonocytic progenitor cells are derived from a source selected from the group consisting of bone marrow stem cells, peripheral blood stem cells, cord blood stem cells, fetal liver stem cells and cytokine mobilized stem cells.
- 16. The method of claim 15 wherein the pre-dendritic myelomonocytic progenitor cells are derived from bone marrow.
- 17. The method of claim 13 wherein the pre-dendritic myelomonocytic progenitor cells are cultured in the absence of any other growth factor besides EDHF.
- 18. The method of claim 13 wherein the EDHF is present in the culture medium in an amount of from about 0.1 μg/mL to about 200 μg/mL.
- 19. The method of claim 13 wherein the pre-dendritic myelomonocytic progenitor cells are cultured in the presence of one or more additional hematopoietic growth factors in addition to the EDHF.
- 20. The method of claim 19 wherein the additional hematopoietic growth factors are selected from the group consisting of IL-3, GM-CSF, SCF, EPO, G-CSF, IL-1, IL-6, IL-3, IL-4, TNF-α and FLT3 ligand.
Parent Case Info
[0001] This application claims benefit of Provisional Application No. 60/348,903 filed Oct. 26, 2001, Provisional Application No. 60/344,680 filed Oct. 31, 2001, Provisional Application No. 60/338,309 filed Dec. 6, 2001, Provisional Application No. 60/364,799 filed Mar. 15, 2002, and Provisional Application No. 60/372,498 filed Apr. 11, 2002; the disclosures of which are incorporated herein by reference.
Provisional Applications (5)
|
Number |
Date |
Country |
|
60348903 |
Oct 2001 |
US |
|
60344680 |
Oct 2001 |
US |
|
60338309 |
Dec 2001 |
US |
|
60364799 |
Mar 2002 |
US |
|
60372498 |
Apr 2002 |
US |